Business
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, was invited to appear as a featured guest on the Big Biz Show, an Emmy Award-winning nationally syndicated radio and TV program. The show aired on Wednesday, October 15, 2025, and air
About this update from Adial Pharmaceuticals, Inc
[{"type":"image","alt":"Adial Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Adial Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fKhTAZbrVcry7QkXYXjJNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8","width":282,"height":123}},"lazy":false},{"type":"text","content":"GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, was invited to appear as a featured guest on the Big Biz Show, an Emmy Award-winning nationally syndicated radio and TV program.","length":445,"tagName":"p"},{"type":"text","content":"The show aired on Wednesday, October 15, 2025, and aired on cable TV on Fox Business, NBCUniversal, and Time Warner Cable, and streaming services, including Roku, Apple TV, fire TV, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio and iHeart Media in 175 countries. Additionally, the show is available on the Company’s website here: www.adial.com/newsroom.","length":378,"tagName":"p"},{"type":"text","content":"About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional ...